Skip to main content
Top
Published in: Inflammation 6/2012

01-12-2012

Heparin Rescues Sepsis-Associated Acute Lung Injury and Lethality Through the Suppression of Inflammatory Responses

Authors: Dongmei Zhao, Renyu Ding, Yiran Mao, Liang Wang, Zhidan Zhang, Xiaochun Ma

Published in: Inflammation | Issue 6/2012

Login to get access

Abstract

Heparin, a potent blood anticoagulant, is known to possess anti-inflammatory activity. In this work, we investigated whether heparin can ameliorate acute lung injury and lethal response in lipopolysaccharide (LPS)-induced mouse model of sepsis. We found that heparin effectively rescued lethality, improved lung pathological changes, inhibited myeloperoxidase (MPO) activity, and reduced malondialdehyde (MDA) level, lung wet/dry weight ratio and Evans blue values in LPS-induced septic mice. In addition, heparin also inhibited the release of tumor necrosis factor (TNF)-α, interleukin-6 (IL-6) and IL-1β in serum and decreased the expression of p-p38, nuclear factor κB (NF-κB) and p-c-SRC kinase in lungs of septic mice. Our findings suggest that heparin is capable of suppressing the lethal response and acute lung injury associated with sepsis, and support the notion that heparin may be a potential therapeutic agent for the conditions associated with septic shock.
Literature
2.
go back to reference Fry, D.E. 2012. Sepsis, systemic inflammatory response, and multiple organ dysfunction: The mystery continues. The American Surgeon 78(1): 1–8.PubMed Fry, D.E. 2012. Sepsis, systemic inflammatory response, and multiple organ dysfunction: The mystery continues. The American Surgeon 78(1): 1–8.PubMed
4.
go back to reference Netea, M.G., J.W. van der Meer, M. van Deuren, and B.J. Kullberg. 2003. Proinflammatory cytokines and sepsis syndrome: Not enough, or too much of a good thing? Trends in Immunology 24(5): 254–258.PubMedCrossRef Netea, M.G., J.W. van der Meer, M. van Deuren, and B.J. Kullberg. 2003. Proinflammatory cytokines and sepsis syndrome: Not enough, or too much of a good thing? Trends in Immunology 24(5): 254–258.PubMedCrossRef
5.
go back to reference Abraham, E., A. Carmody, R. Shenkar, and J. Arcaroli. 2000. Neutrophils as early immunologic effectors in hemorrhage- or endotoxemia-induced acute lung injury. American Journal of Physiology. Lung Cellular and Molecular Physiology 279(6): L1137–L1145.PubMed Abraham, E., A. Carmody, R. Shenkar, and J. Arcaroli. 2000. Neutrophils as early immunologic effectors in hemorrhage- or endotoxemia-induced acute lung injury. American Journal of Physiology. Lung Cellular and Molecular Physiology 279(6): L1137–L1145.PubMed
6.
go back to reference Silva, E., J. Arcaroli, Q. He, D. Svetkauskaite, C. Coldren, J.A. Nick, K. Poch, J.S. Park, A. Banerjee, and E. Abraham. 2007. HMGB1 and LPS induce distinct patterns of gene expression and activation in neutrophils from patients with sepsis-induced acute lung injury. Intensive Care Medicine 33(10): 1829–1839. doi:10.1007/s00134-007-0748-2.PubMedCrossRef Silva, E., J. Arcaroli, Q. He, D. Svetkauskaite, C. Coldren, J.A. Nick, K. Poch, J.S. Park, A. Banerjee, and E. Abraham. 2007. HMGB1 and LPS induce distinct patterns of gene expression and activation in neutrophils from patients with sepsis-induced acute lung injury. Intensive Care Medicine 33(10): 1829–1839. doi:10.​1007/​s00134-007-0748-2.PubMedCrossRef
8.
go back to reference Hirsh, J., S.S. Anand, J.L. Halperin, and V. Fuster. 2001. Guide to anticoagulant therapy: Heparin: A statement for healthcare professionals from the American Heart Association. Circulation 103(24): 2994–3018.PubMedCrossRef Hirsh, J., S.S. Anand, J.L. Halperin, and V. Fuster. 2001. Guide to anticoagulant therapy: Heparin: A statement for healthcare professionals from the American Heart Association. Circulation 103(24): 2994–3018.PubMedCrossRef
11.
go back to reference Wang, M., J. He, B. Mei, X. Ma, and Z. Huo. 2008. Therapeutic effects and anti-inflammatory mechanisms of heparin on acute lung injury in rabbits. Academic Emergency Medicine 15(7): 656–663.PubMedCrossRef Wang, M., J. He, B. Mei, X. Ma, and Z. Huo. 2008. Therapeutic effects and anti-inflammatory mechanisms of heparin on acute lung injury in rabbits. Academic Emergency Medicine 15(7): 656–663.PubMedCrossRef
13.
go back to reference Weng, T.I., H.Y. Wu, C.W. Kuo, and S.H. Liu. 2011. Honokiol rescues sepsis-associated acute lung injury and lethality via the inhibition of oxidative stress and inflammation. Intensive Care Medicine 37(3): 533–541. doi:10.1007/s00134-010-2104-1.PubMedCrossRef Weng, T.I., H.Y. Wu, C.W. Kuo, and S.H. Liu. 2011. Honokiol rescues sepsis-associated acute lung injury and lethality via the inhibition of oxidative stress and inflammation. Intensive Care Medicine 37(3): 533–541. doi:10.​1007/​s00134-010-2104-1.PubMedCrossRef
14.
15.
go back to reference Cannon, J.G., R.G. Tompkins, J.A. Gelfand, H.R. Michie, G.G. Stanford, J.W. van der Meer, S. Endres, G. Lonnemann, J. Corsetti, B. Chernow, et al. 1990. Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever. The Journal of Infectious Diseases 161(1): 79–84.PubMedCrossRef Cannon, J.G., R.G. Tompkins, J.A. Gelfand, H.R. Michie, G.G. Stanford, J.W. van der Meer, S. Endres, G. Lonnemann, J. Corsetti, B. Chernow, et al. 1990. Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever. The Journal of Infectious Diseases 161(1): 79–84.PubMedCrossRef
16.
go back to reference Minamino, T., and I. Komuro. 2006. Regeneration of the endothelium as a novel therapeutic strategy for acute lung injury. The Journal of Clinical Investigation 116(9): 2316–2319. doi:10.1172/JCI29637.PubMedCrossRef Minamino, T., and I. Komuro. 2006. Regeneration of the endothelium as a novel therapeutic strategy for acute lung injury. The Journal of Clinical Investigation 116(9): 2316–2319. doi:10.​1172/​JCI29637.PubMedCrossRef
17.
18.
go back to reference Blackwell, T.S., T.R. Blackwell, E.P. Holden, B.W. Christman, and J.W. Christman. 1996. In vivo antioxidant treatment suppresses nuclear factor-kappa B activation and neutrophilic lung inflammation. The Journal of Immunology 157(4): 1630–1637.PubMed Blackwell, T.S., T.R. Blackwell, E.P. Holden, B.W. Christman, and J.W. Christman. 1996. In vivo antioxidant treatment suppresses nuclear factor-kappa B activation and neutrophilic lung inflammation. The Journal of Immunology 157(4): 1630–1637.PubMed
19.
go back to reference Liu, S.F., X. Ye, and A.B. Malik. 1999. Inhibition of NF-kappaB activation by pyrrolidine dithiocarbamate prevents In vivo expression of proinflammatory genes. Circulation 100(12): 1330–1337.PubMedCrossRef Liu, S.F., X. Ye, and A.B. Malik. 1999. Inhibition of NF-kappaB activation by pyrrolidine dithiocarbamate prevents In vivo expression of proinflammatory genes. Circulation 100(12): 1330–1337.PubMedCrossRef
20.
go back to reference Lee, H.S., H.J. Kim, C.S. Moon, Y.H. Chong, and J.L. Kang. 2004. Inhibition of c-Jun NH2-terminal kinase or extracellular signal-regulated kinase improves lung injury. Respiratory Research 5: 23. doi:10.1186/1465-9921-5-23.PubMedCrossRef Lee, H.S., H.J. Kim, C.S. Moon, Y.H. Chong, and J.L. Kang. 2004. Inhibition of c-Jun NH2-terminal kinase or extracellular signal-regulated kinase improves lung injury. Respiratory Research 5: 23. doi:10.​1186/​1465-9921-5-23.PubMedCrossRef
21.
go back to reference Abu-Amer, Y., F.P. Ross, K.P. McHugh, A. Livolsi, J.F. Peyron, and S.L. Teitelbaum. 1998. Tumor necrosis factor-alpha activation of nuclear transcription factor-kappaB in marrow macrophages is mediated by c-Src tyrosine phosphorylation of Ikappa Balpha. The Journal of Biological Chemistry 273(45): 29417–29423.PubMedCrossRef Abu-Amer, Y., F.P. Ross, K.P. McHugh, A. Livolsi, J.F. Peyron, and S.L. Teitelbaum. 1998. Tumor necrosis factor-alpha activation of nuclear transcription factor-kappaB in marrow macrophages is mediated by c-Src tyrosine phosphorylation of Ikappa Balpha. The Journal of Biological Chemistry 273(45): 29417–29423.PubMedCrossRef
22.
go back to reference Fan, C., Q. Li, D. Ross, and J.F. Engelhardt. 2003. Tyrosine phosphorylation of I kappa B alpha activates NF kappa B through a redox-regulated and c-Src-dependent mechanism following hypoxia/reoxygenation. The Journal of Biological Chemistry 278(3): 2072–2080. doi:10.1074/jbc.M206718200M206718200.PubMedCrossRef Fan, C., Q. Li, D. Ross, and J.F. Engelhardt. 2003. Tyrosine phosphorylation of I kappa B alpha activates NF kappa B through a redox-regulated and c-Src-dependent mechanism following hypoxia/reoxygenation. The Journal of Biological Chemistry 278(3): 2072–2080. doi:10.​1074/​jbc.​M206718200M20671​8200.PubMedCrossRef
23.
go back to reference Kang, J.L., H.J. Jung, K. Lee, and H.R. Kim. 2006. Src tyrosine kinases mediate crystalline silica-induced NF-kappaB activation through tyrosine phosphorylation of IkappaB-alpha and p65 NF-kappaB in RAW 264.7 macrophages. Toxicological Sciences 90(2): 470–477. doi:10.1093/toxsci/kfj096.PubMedCrossRef Kang, J.L., H.J. Jung, K. Lee, and H.R. Kim. 2006. Src tyrosine kinases mediate crystalline silica-induced NF-kappaB activation through tyrosine phosphorylation of IkappaB-alpha and p65 NF-kappaB in RAW 264.7 macrophages. Toxicological Sciences 90(2): 470–477. doi:10.​1093/​toxsci/​kfj096.PubMedCrossRef
24.
go back to reference Kang, J.L., H.W. Lee, H.J. Kim, H.S. Lee, V. Castranova, C.M. Lim, and Y. Koh. 2005. Inhibition of SRC tyrosine kinases suppresses activation of nuclear factor-kappaB, and serine and tyrosine phosphorylation of IkappaB-alpha in lipopolysaccharide-stimulated raw 264.7 macrophages. Journal of Toxicology and Environmental Health. Part A 68(19): 1643–1662. doi:10.1080/15287390500192114.PubMedCrossRef Kang, J.L., H.W. Lee, H.J. Kim, H.S. Lee, V. Castranova, C.M. Lim, and Y. Koh. 2005. Inhibition of SRC tyrosine kinases suppresses activation of nuclear factor-kappaB, and serine and tyrosine phosphorylation of IkappaB-alpha in lipopolysaccharide-stimulated raw 264.7 macrophages. Journal of Toxicology and Environmental Health. Part A 68(19): 1643–1662. doi:10.​1080/​1528739050019211​4.PubMedCrossRef
25.
go back to reference Lee, H.S., C. Moon, H.W. Lee, E.M. Park, M.S. Cho, and J.L. Kang. 2007. Src tyrosine kinases mediate activations of NF-kappaB and integrin signal during lipopolysaccharide-induced acute lung injury. The Journal of Immunology 179(10): 7001–7011.PubMed Lee, H.S., C. Moon, H.W. Lee, E.M. Park, M.S. Cho, and J.L. Kang. 2007. Src tyrosine kinases mediate activations of NF-kappaB and integrin signal during lipopolysaccharide-induced acute lung injury. The Journal of Immunology 179(10): 7001–7011.PubMed
26.
Metadata
Title
Heparin Rescues Sepsis-Associated Acute Lung Injury and Lethality Through the Suppression of Inflammatory Responses
Authors
Dongmei Zhao
Renyu Ding
Yiran Mao
Liang Wang
Zhidan Zhang
Xiaochun Ma
Publication date
01-12-2012
Publisher
Springer US
Published in
Inflammation / Issue 6/2012
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-012-9503-0

Other articles of this Issue 6/2012

Inflammation 6/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.